(Press-News.org) LOS ALAMOS, N.M., Feb. 19, 2013—A study by researchers from Los Alamos National Laboratory and a multinational team reveals how daclatasvir, a direct-acting antiviral agent in development for the treatment of hepatitis C virus (HCV), targets one of its proteins and causes the fastest viral decline ever seen with anti-HCV drugs – within 12 hours of treatment.
Chronic infection with hepatitis C virus affects about 150 million people worldwide. It is the leading cause of cirrhosis, liver cancer and liver transplants and results in some 350,000 deaths worldwide every year.
The team's work reveals that daclatasvir has two primary modes of action against HCV and also provides a more accurate estimate of the HCV half-life. Until 2011, treatment options were limited and offered modest effectiveness; fewer than half of treated patients were fully cured of the virus. In the last decade, active research on understanding the mechanisms of HCV replication resulted in the discovery of direct acting antivirals targeting all stages of the viral replication process.
The new mathematical analysis of the rapid viral decline observed after one dose of daclatasvir reveals that the drug blocks two stages of the viral lifecycle and that the HCV half-life in serum is four times shorter than previously thought according to a study published in Proceedings of the National Academy of Sciences USA.
The NS5A protein within the hepatitis virus is a specific target for drug development. The first NS5A inhibitor, daclatasvir, developed by Bristol Myers Squibb, showed one of the most potent effects in combating HCV; one dose led to a thousand-fold decrease in viral levels within about 12 hours. Oddly, however NS5A has no known enzymatic functions making it difficult to understand its mode of action and design optimal drug combinations.
"Unraveling how this drug could cause such a rapid drop in the amount of virus in an infected person's blood could greatly enhance our ability to design optimal drug therapies and ultimately cure this disease," said Alan Perelson, senior author on the paper and a senior fellow at Los Alamos National Laboratory.
A mathematical method called "viral kinetic modeling" aims to characterize the main mechanisms that govern the virologic response to treatment. It is instrumental in understanding HCV pathogenesis and in guiding development of a variety of anti-HCV agents.
Until now, viral kinetic models did not take into account the intracellular events during viral replication and infected cells were considered as "black boxes" whose viral production was partially shut down by treatment.
The researchers demonstrated that understanding the effects of daclatasvir in vivo requires a novel modeling approach that incorporates drug effects on the HCV intracellular lifecycle. They used this new model to characterize the viral kinetics during daclatasvir therapy and they showed that this compound efficiently blocked two distinct processes, namely the synthesis of new viral genomes (like other antivirals) but also the release of the virus from infected cells.
As a consequence of this unique mode of action, the viral decline observed during treatment with daclatasvir allowed for more precise estimation of the HCV half-life in serum, about 45 minutes, instead of the previously estimated 2.7 hours. This implies that the daily viral production; and thus the risk of mutations conferring drug resistance, is four times larger than previously thought.
###
About the team
The study is by researchers Alan S. Perelson from Los Alamos National Laboratory, Susan L. Uprichard and Natasha Sansone from University of Illinois at Chicago; Harel Dahari, Thomas Layden and Scott J. Cotler from Loyola University, Chicago; Richard Nettles from Bristol-Myers Squibb and Jeremie Guedj from Institut National de la Santé et de la Recherche Médicale, France.
The research was funded by National Institutes of Health, the National Science Foundation and the University of Illinois Walter Payton Liver Center Guild.
Link to paper online: "Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life."
About Los Alamos National Laboratory
Los Alamos National Laboratory, a multidisciplinary research institution engaged in strategic science on behalf of national security, is operated by Los Alamos National Security, LLC, a team composed of Bechtel National, the University of California, The Babcock & Wilcox Company, and URS for the Department of Energy's National Nuclear Security Administration.
Los Alamos enhances national security by ensuring the safety and reliability of the U.S. nuclear stockpile, developing technologies to reduce threats from weapons of mass destruction, and solving problems related to energy, environment, infrastructure, health, and global security concerns.
Computer modeling reveals how surprisingly potent hepatitis C drug works
2013-02-20
ELSE PRESS RELEASES FROM THIS DATE:
UCLA scientists develop new therapeutics that could accelerate wound healing
2013-02-20
In "before" and "after" photos from advertisements for wound-healing ointments, bandages and antibiotic creams, we see an injury transformed from an inflamed red gash to smooth and flawless skin.
What we don't appreciate is the vital role that our own natural biomolecules play in the healing process, including their contribution to the growth of new cells and the development of new blood vessels that provide nutrients to those cells.
Now, UCLA researchers led by Heather Maynard, a professor of chemistry and biochemistry and a member of UCLA's California NanoSystems ...
UCLA researchers develop new technique to scale up production of graphene micro-supercapacitors
2013-02-20
While the demand for ever-smaller electronic devices has spurred the miniaturization of a variety of technologies, one area has lagged behind in this downsizing revolution: energy-storage units, such as batteries and capacitors.
Now, Richard Kaner, a member of the California NanoSystems Institute at UCLA and a professor of chemistry and biochemistry, and Maher El-Kady, a graduate student in Kaner's laboratory, may have changed the game.
The UCLA researchers have developed a groundbreaking technique that uses a DVD burner to fabricate micro-scale graphene-based supercapacitors ...
Sweeping the dust from a cosmic lobster
2013-02-20
Located around 8000 light-years away in the constellation of Scorpius (The Scorpion), NGC 6357 -- sometimes nicknamed the Lobster Nebula [1] due to its appearance in visible-light images -- is a region filled with vast clouds of gas and tendrils of dark dust. These clouds are forming stars, including massive hot stars which glow a brilliant blue-white in visible light.
This image uses infrared data from ESO's Visible and Infrared Survey Telescope for Astronomy (VISTA) at the Paranal Observatory in Chile. It is just a small part of a huge survey called VISTA Variables ...
Human cognition depends upon slow-firing neurons
2013-02-20
Good mental health and clear thinking depend upon our ability to store and manipulate thoughts on a sort of "mental sketch pad." In a new study, Yale School of Medicine researchers describe the molecular basis of this ability — the hallmark of human cognition — and describe how a breakdown of the system contributes to diseases such as schizophrenia and Alzheimer's disease.
"Insults to these highly evolved cortical circuits impair the ability to create and maintain our mental representations of the world, which is the basis of higher cognition," said Amy Arnsten, professor ...
'Inspiring' teens with 'research virus': Expert-mentored bioscience contest proves a powerful vector
2013-02-20
Testimonials and responses to a survey from 375 past teen participants in a Canadian biotechnology competition -- mentored in professional labs by expert scientists -- show a majority of respondents were influenced by the experience to pursue science research studies and careers, offering a model for countries worldwide to advance their health and economic interests.
In a survey of 375 past participants by Bioscience Education Canada, which runs the "Sanofi BioGENEius Challenge Canada," 84% said their participation helped determine their field of study or career plan; ...
Fragile X makes brain cells talk too much
2013-02-20
The most common inherited form of mental retardation and autism, fragile X syndrome, turns some brain cells into chatterboxes, scientists at Washington University School of Medicine in St. Louis report.
The extra talk may make it harder for brain cells to identify and attend to important signals, potentially establishing an intriguing parallel at the cellular level to the attention problems seen in autism.
According to the researchers, understanding the effects of this altered signaling will be important to developing successful treatments for fragile X and autism.
"We ...
Cost of medication and stigma leading asthma sufferers to risk health
2013-02-20
The high cost of medication, stigmatisation and poor acceptance of their condition are causing young adults to take a dangerous approach to managing their asthma, according to new research published today in the journal BMJ Open.
In the UK 5.4 million people are currently receiving treatment for asthma: 1.1 million children (one in 11) and 4.3 million adults (one in 12). There were 1,131 deaths from asthma in the UK in 2009. Most asthma deaths are preventable.
Despite the availability of effective treatments, poor asthma control is common.
The overuse of short-acting ...
Simple measures to promote sleep can reduce delirium in intensive care patients
2013-02-20
A hospital is not the best place to get a good night's sleep, especially in a noisy intensive care unit. It's a cause for concern because studies have shown that a lack of sleep can cause patients to experience delirium—an altered mental state that may delay their recovery and lead to short and long-term confusion and memory problems.
A team of doctors, nurses, psychologists and pharmacists in the medical intensive care unit (MICU) at The Johns Hopkins Hospital implemented a project to see if by taking simple steps to reduce nighttime noise, light,and staff interruptions, ...
Tool boosts success of online collaborations by redistributing the burdens of leadership
2013-02-20
PITTSBURGH—The Web makes it possible for lots of people to collaborate on projects, but it doesn't make it easy to lead them. A Carnegie Mellon University researcher has developed a new tool that helps leaders see complex, collaborative projects through to completion by redistributing leadership responsibilities.
The tool, called Pipeline, makes it easier to assign, critique and track the progress of individual tasks within a project and makes it easy for leaders to delegate responsibility to others. As evidenced by a case study in which Pipeline was used to manage the ...
First signals from brain nerve cells with ultrathin nanowires
2013-02-20
Electrodes operated into the brain are today used in research and to treat diseases such as Parkinson's. However, their use has been limited by their size. At Lund University in Sweden, researchers have, for the first time, succeeded in implanting an ultrathin nanowire-based electrode and capturing signals from the nerve cells in the brain of a laboratory animal.
The researchers work at Lund University's Neuronano Research Centre in an interdisciplinary collaboration between experts in subjects including neurophysiology, biomaterials, electrical measurements and nanotechnology. ...